Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
The synergism of voriconazole (VRC) and terbinafine was studied by using 39 genotypically defined clinical Candida albicans isolates that were cross-resistant to fluconazole and VRC and serial isolates that gradually developed azole resistance. Synergy was noticed in 100% (eight of eight) of the strains that were resistant to VRC. Antagonism was not observed.
Weig
M
M
Department of Bacteriology, University of Göttingen, Göttingen, Germany. mweig@gwdg.de
Müller
F M
FM
D017088:AIDS-Related Opportunistic Infections / Q000382:microbiology; D000935:Antifungal Agents / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects*; D002177:Candidiasis / Q000382:microbiology; D004352:Drug Resistance, Microbial / Q000502:physiology; D004357:Drug Synergism; D015658:HIV Infections / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009281:Naphthalenes / Q000494:pharmacology*; D010612:Pharyngitis / Q000382:microbiology; D011743:Pyrimidines / Q000494:pharmacology*; D000077291:Terbinafine; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D009281:Naphthalenes; D011743:Pyrimidines; D014230:Triazoles; D000077291:Terbinafine; D065819:Voriconazole